Newscast – media

How AI Procurement Can Boost Supply Chain Efficiency by 50% in the Pharmaceutical Industry? Drugdu AI is Exploring the Future!

Traditional procurement faces high costs, lack of supply chain transparency, and complex compliance processes. Drugdu AI is developing intelligent procurement solutions to make pharmaceutical B2B purchasing more efficient and smarter! What is Drugdu AI? Drugdu AI is a leading B2B pharmaceutical procurement platform that has built a global database of pharmaceutical suppliers. By leveraging AI-driven decision-making and data-powered supply chain optimization, Drugdu AI aims to enhance matching accuracy and reduce procurement risks. Drugdu AI’s Core Capabilities 1. Global B2B Pharmaceutical Trading Platform Drugdu.com has built a digital procurement ecosystem covering pharmaceuticals, medical devices, and pharmaceutical raw materials. It seamlessly connects manufacturers, suppliers, and buyers worldwide, facilitating efficient cross-border transactions. 2. Intelligent Supply Chain Solutions The platform provides end-to-end services, including precise supplier matching, real-time price transparency, international logistics optimization, and inventory management—significantly shortening procurement cycles and reducing transaction costs. 3. Integrated Compliance & Certification Support Drugdu AI integrates FDA, GMP, ...
- Source: drugdu
- 54
- February 18, 2025
AI DeepSeek Drugdu AI intelligent procurement solutions pharma
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: I. Accurate Market Insights: AI as Your Detective (1) Quickly Identify Customers and Markets: Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. (2) Monitor Competitors in Real-Time: With DeepSeek, ...
- Source: drugdu
- 104
- February 11, 2025
AI DeepSeek Drugdu Pharma Trade
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: Accurate Market Insights: AI as Your Detective Quickly Identify Customers and Markets Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. Monitor Competitors in Real-Time With ...
- Source: drugdu
- 98
- February 10, 2025
AI DeepSeek Drugdu Pharma Trade
Eli Lilly claims that Tilpotide is more effective than Smeaglutide

Lilly stated in a press release on December 4th that in a head to head randomized controlled trial, its weight loss drug Zepbound was more effective in weight loss than its competitor Novo Nordisk’s Wegovy. This result is not surprising for scientists and doctors who are closely monitoring the rise of glucagon like peptide-1 (GLP-1) weight loss drugs. This randomized controlled trial also reflects the results of diabetes drugs from the two companies. These drugs use the same active ingredients and are sold under the brands of Mounjaro and Ozempic respectively. Similar results have been observed in observational studies and previous clinical trials comparing drugs with placebos separately. However, recording the differences between Zepbound and Wegovy in a rigorous manner is still an important step, especially as such a comparison may allow Lilly to claim in marketing that Zepbound has better therapeutic effects. This can help Lilly win ...
- Source: drugdu
- 170
- December 7, 2024
47% more weight loss! Eli Lilly releases “single challenge” semaglutide data

On December 4, local time, Eli Lilly announced the results of the Phase 3b clinical study of SURMOUNT-5. The subjects in the weight loss version of Zepbound lost 50.3 pounds (22.8 kg) at week 72, and the subjects in the weight loss version of Wegovy lost 33.1 pounds (15 kg) during the same period. Compared with semaglutide, the average weight loss effect of Zepbound is 47% higher. SURMOUNT-5 is a multicenter, randomized, open-label, head-to-head study designed to evaluate the efficacy and safety of Zepbound and semaglutide in obese or overweight adults with at least one comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, and without diabetes. A total of 751 participants were recruited in the trial and assigned in a 1:1 ratio to receive the maximum tolerated dose of tirpotide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg). At 72 weeks, the average weight loss ...
- Source: https://mp.weixin.qq.com/
- 141
- December 7, 2024
1 “Parkinson’s new drug” approved for marketing

According to the official website of NMPA, Zambon/Parexel Pharmaceuticals’ Safinamide Mesylate Tablets have been approved for marketing. According to public information, Safinamide is a drug used to treat Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disease and a common activity disorder. Its main cause is a lack of dopamine. According to statistics, about 1-2% of people over 65 years old suffer from Parkinson’s disease worldwide. In China, there are more than 3 million Parkinson’s disease patients, and the incidence rate increases with age. It is predicted that the number of Parkinson’s patients in China will exceed 5 million in 2030. The “OFF” period is a common phenomenon in the middle and late stages of Parkinson’s disease. Patients usually show severe aggravation of symptoms such as muscle stiffness, tremor and movement difficulties. According to statistics, about 75% of Parkinson’s patients in the middle and late stages will ...
- Source: https://news.yaozh.com/archive/44631.html
- 148
- December 7, 2024
Medtronic, new progress in ECMO

On September 26, Medtronic’s official website announced the launch of a new ECMO system called VitalFlow™. This is a configurable single-system ECMO solution built on simplicity and performance. According to the official website, the VitalFlow system has a large, intuitive touch screen that centrally displays real-time performance data, provides configurability, and uses the proven Medtronic Nautilus™ ECMO oxygenator design to achieve long-term stable performance. Medtronic said that the VitalFlow™ ECMO system bridges the gap between bedside care and in-hospital transportation, providing clinicians with an easier and smarter ECMO experience. Dr. Karim Bandali, president of the cardiac surgery business within the Medtronic cardiovascular product portfolio, believes that the VitalFlow system is simple and easy to use, allowing users with different comfort levels to serve patients confidently and efficiently. It can be easily moved between different departments of the hospital and has durable and reliable performance. In March 2024, Medtronic completed ...
- Source: https://mp.weixin.qq.com
- 225
- October 4, 2024
To build China’s own blood brand

In recent years, China’s blood gas analyzer market has shown a strong development trend, especially in critical illness, emergency and surgical scenarios, and the scale has expanded dramatically. At present, the market size of blood gas analysis in China is about 2.7 billion yuan, and the industry growth rate is about 20%. From the perspective of market share, imported brands have the first-mover advantage in R&D and market, according to the data reported by the China Research Institute of Puhua Industry Research Institute, about 80% of the current market share of the domestic blood gas analyzer market is still occupied by imported brands, mainly for Radiometer, Wolfen, Abbott, etc., and domestic brands are mainly represented by the head brand of blood gas. According to the statistics of the bidding network, in the first half of 2024, the scale and demand for blood gas equipment procurement across the country ...
- Source: https://mp.weixin.qq.com
- 216
- October 4, 2024
Optimization strategy for production process of RNA targeted drugs

RNA targeted drugs are a completely new category of drugs that are completely different from small molecule drugs and antibody drugs. On the one hand, they can target mRNA, ncRNA, and other intracellular proteins through gene silencing to inhibit their expression and achieve the goal of treating diseases; On the other hand, new generation vaccines and protein replacement therapies can also be developed based on mRNA. RNA targeted drugs are undoubtedly a strategic frontier in biopharmaceutical innovation, with broad potential application scenarios in the future. The production process technology of mRNA industrialization is particularly important for the widespread application and industrialization of mRNA. Based on this, this article will focus on the optimization strategies for the production process of RNA targeted drugs. Stability chemical modification enhances drug safety and efficacy For RNA targeted drugs, chemical modification (excluding tissue targeting ligands) mainly has two basic functions: firstly, chemical modification can significantly ...
- Source: drugdu
- 195
- October 3, 2024
Seven domestic companies have completed a new round of financing, focusing on the fields of cell and gene therapy

In September, several domestic companies focused on the field of cell and gene therapy (CGT) announced progress in financing. This article will share basic information about its 7 companies based on publicly available materials. Xingsairui has successfully completed tens of millions of yuan in angel round financing On September 14th, Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (hereinafter referred to as “Xingsai Ruizhen”) announced the completion of tens of millions of yuan in angel round financing and officially launched the angel+round financing plan! This round of financing is jointly invested by Fosun Pharma’s Rehabilitation Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund. This round of financing will be used for the continuous promotion of core pipelines and platforms, as well as the construction of the company’s team and research and development laboratories. Xingsai Ruizhen was founded in July 2022 and incubated by the New Drug Innovation ...
- Source: drugdu
- 234
- October 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.